9. Krishnamurti, U. HER2 in breast cancer: a review and update / Krishnamurti, U., Silverman, J. F // Advances in Anatomic Pathology. - 2014. - Vol. 21(2). - P. 100-107. doi:10.1097/pap.0000000000000015
10. Loibl, S. HER2-positive breast cancer / Loibl, S., Gianni, L. // The Lancet. - 2017. - Vol. 389(10087). - P. 2415-2429. doi:10.1016/s0140-6736(16)32417-5
11. HERCEPTIN® (trastuzumab) [Electronic resource] - URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103792s5337lbl.pdf (accessed: 27.02.19)
12. Klapper L.N. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2 / Klapper L.N., Waterman H., Sela M., Yarden Y. // Cancer Res. - 2000. - Vol. 60(13). - P. 3384-3388. PMID: 10910043
13. Fiuza Trastuzumab and cardiotoxicity / M. Fiuza and A. Magalhaes // Cardiotoxicity of oncologic treatments, ISBN: 978-953-51-0273-1, InTech [Electronic resource] - URL: http://www.intechopen.com/books/cardiotoxicity-of-oncologic-treatments/trastuzumab-and-cardiotoxicity (accessed: 27.02.19)
14. Boekhout, A. H. Trastuzumab / Boekhout, A. H., Beijnen, J. H., Schellens, J. H. M. // The Oncologist. - 2011. - Vol. 16(6). - P. 800-810. doi:10.1634/theoncologist.2010-0035
15. Leveque, D. Clinical pharmacology of trastuzumab / Leveque, D., Gigou, L., Bergerat, J. // Current Clinical Pharmacology. - 2008. - Vol. 3(1). - P. 51-55. doi:10.2174/157488408783329931
16. Slamon DJ, Eiermann W, …and On Behalf of the BCIRG-006 Investigators. Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC>T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC>TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl): Abstract nr S5-04.
17. Kristeleit H. Long-term follow-up data from pivotal studies of adjuvant trastuzumab in early breast cancer / Kristeleit H., Parton M., Beresford M. et al. // Targeted Oncology. - 2016. - Vol. 11(5). - P. 579-591. doi:10.1007/s11523-016-0438-5
18. Cameron D. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial / Cameron D., Piccart-Gebhart M. J., Gelber R. D. // The Lancet. - 2017. - Vol. 389(10075). - P. 1195-1205. doi:10.1016/s0140-6736(16)32616-2
19. Suter T. M. Cancer drugs and the heart: importance and management / Suter T. M., Ewer M. S. // European Heart Journal. - 2012. - Vol. 34(15). - P. 1102-1111. doi:10.1093/eurheartj/ehs181
20. Onitilo A. A. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors / Onitilo A. A., Engel J. M., Stankowski R. V. // Therapeutic Advances in Drug Safety. - 2014. - Vol. 5(4). - P. 154-166. doi:10.1177/2042098614529603
21. De Keulenaer G. W. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy / De Keulenaer G. W., Doggen K., Lemmens K. // Circulation Research. - 2010. - Vol. 106(1). - P. 35-46. doi:10.1161/circresaha.109.205906
22. Zeglinski M. Trastuzumab-induced cardiac dysfunction: a “dual-hit” / Zeglinski M., Ludke A., Jassal D.S., Singal P.K. // Experimental & Clinical Cardiology. - 2011. - Vol. 16(3). - P. 70-74. PMID: 22065936
23. Mantarro S. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer / Mantarro S., Rossi M., Bonifazi M. et al. // Internal and Emergency Medicine. - 2015. - Vol. 11(1). - P. 123-140. doi:10.1007/s11739-015-1362-x
24. Jawa Z. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer / Jawa Z., Perez R. M., Garlie L. // Medicine (Baltimore). - 2016. - Vol. 95(44), - e5195. doi:10.1097/md.0000000000005195
25. Zamorano J. L.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines / Zamorano J. L., Lancellotti P., Rodriguez Munoz D. et al. // European Heart Journal. - 2016. - Vol. 37(36). - P. 2768-2801. doi:10.1093/eurheartj/ehw211
26. Cardinale D. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation / Cardinale D., Colombo A., Torrisi R. et al. // Journal of Clinical Oncology. - 2010. - Vol. 28(25). - P. 3910-3916. doi:10.1200/jco.2009.27.3615
27. Ky B. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab / Ky B., Putt M., Sawaya H. // Journal of the American College of Cardiology. - 2014. - Vol. 63(8). - P. 809-816. doi:10.1016/j.jacc.2013.10.061
28. A. Nicolazzi Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer / M.A. Nicolazzi, A. Carnicelli, M. Fuorlo et al. // Eur Rev Med Pharmacol Sci. - 2018. - Vol. 22 (7). - P. 2175-2185. doi:10.26355/eurrev_201804_14752
29. Ledwidge M. Natriuretic peptide-based screening and collaborative care for heart failure / Ledwidge M., Gallagher J., Conlon C. et al. // JAMA. - 2013. - Vol. 310(1). - P. 66-74. doi:10.1001/jama.2013.7588
30. Putt M. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab / Putt M., Hahn V. S., Januzzi J. L. et al. // Clinical Chemistry. - 2015. - Vol. 61(9). - P. 1164-1172. doi:10.1373/clinchem.2015.241232
31. Cardinale D. Anthracycline-induced cardiomyopathy / Cardinale D., Colombo A., Lamantia G. et al. // Journal of the American College of Cardiology. - 2010. - Vol. 55(3). - P. 213-220. doi: 10.1016/j.jacc.2009.03.095
32. Jones A. L. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring / Jones A. L., Barlow M., Barrett-Lee P. J. et al. // British Journal of Cancer. - 2009. - Vol. 100(5). - P. 684-692. doi:10.1038/sj.bjc.6604909
33. Hiller L. Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results / Hiller L., Dunn J. A., Loi S. et al. // BMC Cancer. - 2018. - Vol. 18(1). - P. 391. doi:10.1186/s12885-018-4307-8
34. Pivot X. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial / Pivot X., Romieu G., Debled M. et al. // The Lancet Oncology. - 2013. - Vol. 14(8). - P. 741-748. doi:10.1016/s1470-2045(13)70225-0
35. Kramar A. Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial / Kramar A., Bachelot T., Madrange N. et al. // Annals of Oncology. - 2014. - Vol. 25(8). - P. 1563-1570. doi:10.1093/annonc/mdu177
36. Earl H. M. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results / Earl H. M. et al. // Journal of Clinical Oncology. - 2018. - №36(15 Suppl.). - Abstr. 506. doi:10.1200/JCO.2018.36.15_suppl.506